Browsing Tag
Acute myeloid leukemia
38 posts
TuHURA Biosciences extends runway into 2028 as HURA investors wait for Merkel cell carcinoma data
TuHURA has bought time with a $50m facility. The harder test is whether IFx-2.0 can deliver before HURA investors lose patience.
What the latest ALICE-2 and FRIDA trial results reveal about iadademstat’s AML potential
What do the latest ALICE-2 and FRIDA trial results reveal about iadademstat’s AML potential? Explore the strategic and market implications now.
AACR 2026: Precision Biologics says it found a new weak spot in AML for CAR-NK therapy
Precision Biologics has revealed a new AML CAR-NK target at AACR 2026. Read why truncated O-glycans could matter for future leukemia therapy.
Can Japanese patent leverage strengthen Annamycin’s hand in AML?
Moleculin Biotech secures Japanese patent for Annamycin. Explore how this IP move could shape AML strategy and global commercialization plans.
AVEO Oncology begins Phase 1b/2 ficlatuzumab trial in elderly AML patients via Blood Cancer United collaboration
AVEO Oncology has begun a Beat AML trial for ficlatuzumab in elderly AML patients. See how this could reshape front-line cancer care for high-risk groups.
Amgen (NASDAQ: AMGN) bets on protein degradation with Dark Blue Therapeutics acquisition
Amgen acquires Dark Blue Therapeutics for up to $840M, expanding into MLLT1/3-targeted AML therapies. Find out what this means for oncology innovation today.
Moleculin hits key inflection point as pivotal MIRACLE Phase 3 AML trial completes treatment for first 45 patients
Find out how Moleculin Biotech’s pivotal MIRACLE Phase 3 milestone for Annamycin could reshape treatment for relapsed AML as Q1 2026 data approaches.
Cullinan Therapeutics showcases early AML response with CLN-049 T-cell engager at ASH 2025
Discover how Cullinan Therapeutics’ CLN-049 showed early AML responses at ASH 2025 and what it could mean for future leukemia treatment and investors.
Hanmi Pharmaceutical to acquire Aptose Biosciences in C$2.41-per-share deal with 28% premium
Find out how Hanmi Pharmaceutical’s acquisition of Aptose Biosciences is reshaping the AML treatment landscape today!
Can Moleculin’s MIRACLE trial redefine AML treatment? Company to showcase study at leukemia event
Find out how Moleculin’s MIRACLE phase 3 trial could reshape AML treatment as the company presents its latest progress at the Madrid leukemia meeting.